全血减轻创伤急性凝血病并避免晶体液复苏相关凝血病
研究在麻醉恒河猴多发性创伤失血性休克模型中进行交叉设计复苏,每组6只,比较先全血后晶体液(WB-1st)与先晶体液后全血(CR-1st)两种策略。全血首剂为30分钟内输注50%失血量,晶体液按失血量倍数在30分钟和60分钟内输注。结果显示两组生存、失血量、血流动力学和休克持续时间相当;晶体液输注后血栓弹力图(凝血形成时间、α角、最大血凝块强度)、血小板聚集(对胶原、花生四烯酸、二磷酸腺苷)及血浆凝血(凝血酶原时间、抗凝血酶3、纤维蛋白原)出现异常,而全血输注后这些参数稳定或纠正。作者认为创伤失血性休克中凝血改变在干预前已开始,但晶体液复苏显著加重,或可称为复苏急性凝血病。
要点
- 恒河猴多发性创伤失血性休克模型中,晶体液复苏后血栓弹力图参数(凝血形成时间、α角、最大血凝块强度)出现异常,全血输注后稳定或纠正。
- 晶体液复苏后血小板聚集反应(对胶原、花生四烯酸、二磷酸腺苷)及血浆凝血指标(凝血酶原时间、抗凝血酶3、纤维蛋白原)异常,全血输注后稳定或纠正。
- 两组生存、失血量、血流动力学和休克持续时间相当,凝血改变在干预/复苏前已开始。
- 作者认为晶体液复苏显著加重创伤失血性休克中的凝血异常,或可称为复苏急性凝血病。
- 该研究为转化动物模型(恒河猴,每组6只),结论需在临床中进一步验证。
适用人群与场景
- 麻醉恒河猴多发性创伤失血性休克模型,每组6只,采用交叉设计复苏。
处置流程与药物剂量
- WB-1st策略:30分钟内输注50%失血量,随后30分钟内输注2倍失血量体积的晶体液,再60分钟内输注1倍失血量体积的晶体液。
- CR-1st策略:30分钟内输注2倍失血量体积的晶体液,随后30分钟内输注50%失血量,再60分钟内输注1倍失血量体积的晶体液。
- 在基线、休克结束、第一和第二阶段复苏结束及复苏结束时采血,评估血栓弹力图、血小板聚集和血浆凝血因子。
研究设计与关键结果
- 研究类型:转化动物模型(恒河猴多发性创伤失血性休克),交叉设计,每组6只。
- 干预与对照:WB-1st(先全血后晶体液) vs CR-1st(先晶体液后全血)。
- 主要终点结果:两组生存、失血量、血流动力学和休克持续时间相当。
- 关键次要终点:与基线相比,晶体液输注后第一和第二阶段复苏时间点血栓弹力图(凝血形成时间、α角、最大血凝块强度)、血小板聚集(对胶原、花生四烯酸、二磷酸腺苷)及血浆凝血(凝血酶原时间、抗凝血酶3、纤维蛋白原)出现异常;全血输注后这些参数稳定或纠正。
证据类型、等级与局限
- 证据类型:转化动物模型研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为在创伤和失血性休克中,凝血改变在干预/复苏前已开始,但晶体液复苏显著加重这些改变,或可称为复苏急性凝血病。
- 原文未据此给出临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: The contributions of type and timing of fluid resuscitation to coagulopathy in trauma remain controversial. As part of a multifunctional resuscitation fluid research effort, we sought to further characterize the coagulation responses to resuscitation, specifically as compared to whole blood. We hypothesized that early whole blood administration mitigates the acute coagulopathy of trauma by avoiding the coagulopathy of CR resuscitation.
METHODS: Anesthetized rhesus macaques underwent polytraumatic, hemorrhagic shock, then a crossover study design resuscitation (n = 6 each) with either whole blood first (WB-1st) followed by crystalloid (CR); or CR-1st followed by WB. Resuscitation strategies were the following: WB-1st received 50% shed blood in 30minutes, followed by twice the shed blood volume (SBV) of CR over 30minutes and one times the SBV CR over 60minutes, where CR-1st received twice the SBV of CR over 30minutes, followed by 50% of shed blood in 30minutes, and one times the SBV CR over 60minutes. Blood samples were collected at baseline, end-of-shock, end-of-first and end-of-second resuscitation stages, and end-of-resuscitation for assessment (thromboelastometry, platelet aggregation, and plasmatic coagulation factors). Statistical analyses were conducted using two-way analysis of variance ANOVA with Bonferroni correction and t-tests; significance was at p < 0.05.
RESULTS: Survival, blood loss, hemodynamics, and shock duration were equivalent between the groups. Compared to baseline, parameters measured at first and second resuscitation stage time points directly following CR infusion revealed abnormalities in thromboelastometry (clot formation time, α angle, and maximum clot firmness), platelet aggregation response (to collagen, arachidonic acid, and adenosine diphosphate), and plasmatic coagulation (prothrombin time, anti-thrombin 3, and fibrinogen), while whole blood infusion resulted in stabilization or correction of these parameters following its administration.
CONCLUSIONS: These data suggest that in the setting of trauma and hemorrhagic shock, the coagulation alterations begin before intervention/resuscitation; however, these are significantly aggravated by CR resuscitation and could perhaps be best termed acute coagulopathy of resuscitation.
STUDY TYPE: Translational animal model.
参考来源
- Sheppard FR, Schaub LJ, Cap AP, et al. Whole blood mitigates the acute coagulopathy of trauma and avoids the coagulopathy of crystalloid resuscitation. J Trauma Acute Care Surg. 2018. PMID: 30124622. doi:10.1097/TA.0000000000002046
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。